Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ernst & Young: “Optionality” Here To Stay, As Biotech Business Model Reinvents Itself

This article was originally published in The Pink Sheet Daily

Executive Summary

Chaos in the capital markets may force shortened R&D timelines that result in structured acquisitions, novel deal structures, and a boom in personalized medicine.

You may also be interested in...



Deal-Making Perspectives: GSK/Pfizer HIV Venture Offers Transformational Strategy

Real innovation in deal-making, like pharma R&D, is a rare commodity. As with R&D, deal-making innovation often gets blocked by entrenched interests or misunderstanding or simple inertia. There are lots of reasons not to repeat the single most innovative and successful transaction of all time - Genentech/Roche - but none of them outweigh the spectacular opportunity that deal created

Deal-Making Perspectives: GSK/Pfizer HIV Venture Offers Transformational Strategy

Real innovation in deal-making, like pharma R&D, is a rare commodity. As with R&D, deal-making innovation often gets blocked by entrenched interests or misunderstanding or simple inertia. There are lots of reasons not to repeat the single most innovative and successful transaction of all time - Genentech/Roche - but none of them outweigh the spectacular opportunity that deal created

Ernst & Young: Pricing Pressure Trumps Drug Safety As Industry’s Top Worry

Reimbursement now “end goal of a firm’s clinical development efforts,” risk report says.

Topics

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel